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OBJECTIVE—Smoking decreases insulin action and increases
the risk of type 2 diabetes in humans. Mechanisms responsible
for smoking-induced insulin resistance are unclear. We hypoth-
esized smokers would have increased intramuscular triglyceride
(IMTG) and diacylglycerol (DAG) concentration and decreased
fractional synthesis rate (FSR) compared with nonsmokers.
RESEARCH DESIGN AND METHODS—Nonsmokers (n  18,
aged 20  0.5 years, BMI 22  0.4 kg/m
2, body fat 20  2%, 0
cigarettes per day) and smokers (n  14, aged 21  0.7 years,
BMI 23  0.4 kg/m
2, body fat 20  3%, 18  0.7 cigarettes per
day) were studied in a fasted condition after a standardized diet.
[U-
13C]palmitate was infused during4ho frest followed by a
skeletal muscle biopsy and intravenous glucose tolerance test.
RESULTS—Smokers were less insulin sensitive (Si) compared
with nonsmokers (Si 5.28  0.5 nonsmokers vs. 3.74  0.3
smokers 10
4  U
1  ml
1, P  0.03). There were no differences
in IMTG or DAG concentration (IMTG 24.2  3.4 nonsmokers vs.
27.2  5.9 smokers g/mg dry wt, DAG 0.34  0.02 nonsmokers
vs. 0.35  0.02 smokers g/mg dry wt) or IMTG FSR between
groups (0.66  0.1 nonsmokers vs. 0.55  0.09 smokers %/hr).
Intramuscular lipid composition was different, with increased
percent saturation of IMTG (32.1  1.2 nonsmokers vs. 35.2  1.0
smokers %, P  0.05) and DAG (52.8  1.7 nonsmokers vs. 58.8 
2.2 smokers %, P  0.04) in smokers. Smokers had signiﬁcantly
decreased peroxisome proliferator–activated receptor- (1.76 
0.1 nonsmokers vs. 1.42  0.11 smokers arbitrary units [AU], P 
0.03) and increased monocyte chemotactic protein-1 (3.11  0.41
nonsmokers vs. 4.83  0.54 smokers AU, P  0.02) mRNA
expression compared with nonsmokers. We also found increased
insulin receptor substrate-1 Ser
636 phosphorylation in smokers
compared with nonsmokers (0.73  0.08 nonsmokers vs. 1.14 
0.09 smokers AU, P  0.002).
CONCLUSIONS—These data suggest: 1) IMTG concentration
and turnover are not related to alterations in insulin action in
smokers compared to nonsmokers, 2) increased saturation of
IMTG and DAG in skeletal muscle may be related to insulin
action, and 3) basal inhibition of insulin receptor substrate-1 may
decrease insulin action in smokers. Diabetes 58:2220–2227,
2009
T
he latest data from the Centers for Disease
Control and Prevention indicate 19.8% of the U.S.
population smokes cigarettes (1). Cigarette
smoking is an independent risk factor for the
development of type 2 diabetes (2,3), likely because over-
whelming evidence indicates smoking promotes insulin
resistance (4–9). Nevertheless, the mechanistic link be-
tween smoking and insulin resistance is not clear. Under-
standing the mechanisms of how smoking promotes
insulin resistance may provide drug targets for diabetes
treatment or prevention in people for whom smoking
cessation cannot be achieved.
Intramuscular triglyceride (IMTG) concentration may
be an important marker of skeletal muscle insulin resis-
tance as the content of IMTG is negatively associated with
insulin-stimulated glucose disposal in healthy humans
(10), individuals with type 1 diabetes (11) and type 2
diabetes (12), and offspring of individuals with type 2
diabetes (13). Others (14,15) speculated that in addition to
total content, low rates of IMTG synthesis and degrada-
tion, rather than concentration, may more closely relate to
insulin action. There are several mechanisms that may
increase IMTG storage in smokers, including increased
free fatty acid (FFA) appearance rate, concentration, and
delivery to skeletal muscle (16,17) as well as decreased
adipocyte but increased skeletal muscle lipoprotein
lipase activity (16,18), with similar fat oxidation com-
pared with nonsmokers (17). These data suggest smok-
ing may increase trafﬁcking of fat from adipose tissue to
skeletal muscle, which may enhance IMTG storage and
help explain insulin resistance in smokers compared
with nonsmokers.
Although there have been many investigations on met-
abolic alterations with smoking, the relationship between
smoking, insulin resistance, and intramuscular lipid me-
tabolism has not been explored. Investigating IMTG me-
tabolism in smokers compared with nonsmokers may
allow a more thorough understanding of insulin action in
smokers to better target therapies to prevent and treat
type 2 diabetes. Insight may also be obtained for mecha-
nisms promoting insulin resistance induced by second-
hand smoke exposure (19). We performed this study to
test the hypothesis that IMTG concentration would be
greater and fractional synthesis rate lower in cigarette
smokers compared with nonsmokers. We predicted
decreased insulin action in smokers would be related
to decreased IMTG synthesis compared with control
subjects.
RESEARCH DESIGN AND METHODS
Eighteen healthy sedentary nonsmokers (11 men, 7 women) and 14 smokers
(12 men, 2 women) were recruited for this study (Table 1). Subjects gave
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2220 DIABETES, VOL. 58, October 2009 diabetes.diabetesjournals.orgwritten informed consent and were excluded if they had a BMI  20 kg/m
2 or
25 kg/m
2; diabetes; hyperlipidemia; liver, kidney, thyroid or lung disease; or
were taking medications that can affect glucose or lipid metabolism. Smokers
had been smoking cigarettes for an average of 3.3  0.7 years. All subjects
were sedentary and engaged in moderate to vigorous exercise 3 h/week.
Subjects were weight stable in the 6 months before the study. This study was
approved by the Colorado Multiple Institution Review Board at the University
of Colorado Denver.
Preliminary testing. Subjects reported to the General Clinical Research
Center (GCRC) for screening procedures after a 12-h overnight fast, where
they were given a health and physical exam followed by a fasting blood draw.
Body composition was determined using dual-energy X-ray absorptiometry
(DEXA) analysis (Lunar DPX-IQ; Lunar, Madison, WI).
Diet and exercise control. All subjects were given a prescribed diet for 3
days before admission to the GCRC. Daily caloric requirement was estimated
from the DEXA measurement of fat-free mass using the equation 1.4  [372 	
(23.9  fat-free mass)] and analysis of dietary records. Composition of this
diet was 55% carbohydrate, 30% fat, and 15% protein. The fat content of the
diet was controlled with the composition of saturated, monounsaturated, and
polyunsaturated fat in a 1:1:1 ratio. Subjects were asked to refrain from
planned physical activity for 48 h before the tracer infusion study.
Tracer infusion study. Subjects arrived to the GCRC after an overnight fast
at 7 A.M., when an antecubital vein in one arm was cannulated for isotope
infusion and a retrograde dorsal hand vein in the contralateral side was
catheterized for blood sampling via the heated hand technique. At 7:30 A.M.,
blood and breath samples were taken for background isotope enrichment.
Starting at 8 A.M., a primed (4.5 mg/kg) constant (0.03 mg  kg
1  min
1)
infusion of [6,6-
2H2]glucose and a continuous infusion of [U-
13C] palmitate
(Isotec, Miamisburg, OH) (0.0174 mol  kg
1  min
1) were initiated and
continued for 4 h and throughout the muscle biopsy procedure. Subjects
remained fasting during the tracer infusion. During the 4-h infusion, only
smokers smoked one cigarette (Camel Lights; R.J. Reynolds, Winston-Salem,
NC) every 30 min until the start of the ﬁnal blood sample, for a total of eight
cigarettes. No further smoking occurred throughout the study. Blood sampling
was performed during minutes 210, 220, 230, and 240 of infusion for metab-
olite and hormone concentrations. A percutaneous needle biopsy was per-
formed after 240 min of isotope infusion for determination of IMTG and
diacylglycerol (DAG) concentration, composition, and turnover (20). Muscle
biopsies were taken from midway between the greater trochanter of the femur
and patella. The anatomic location and depth of the biopsy was as similar as
possible among subjects to minimize variance in muscle ﬁber composition
that varies with depth and length in the vastus lateralis (21). Muscle was
immediately ﬂash frozen in liquid nitrogen and stored at 80°C until dissec-
tion and analysis.
After the tracer infusion, insulin sensitivity was determined via an insulin-
modiﬁed frequently sampled intravenous glucose tolerance test using stan-
dard methods (22). Brieﬂy, after baseline samples, intravenous glucose (0.3
g/kg) was infused over 1 min, followed by insulin at 0.03 units/kg 20 min after
glucose administration. Blood samples were then frequently sampled over 3 h
and whole-body insulin sensitivity (Si) calculated using the Bergman minimal
model (22).
Metabolite and hormone analyses. Standard enzymatic assays were used to
measure glucose (Olympus AU400e Chemistry analyzer, Olympus America,
Center Valley, PA), lactate (Sigma Kit #826, St. Louis, MO), and FFA (NEFA
Kit, Wako, TX). Insulin, glucagon, and adiponectin were measured using an
RIA (Diagnostic Systems Laboratories, Webster, TX) and catecholamines
using high-performance liquid chromatography. Plasma cotinine (Calbiotech,
Spring Valley, CA) as well as interleukin (IL)-6 and tumor necrosis factor
(TNF)-
 (R&D Systems HS600B and HSTA00C, respectively, Minneapolis,
MN) were measured using an ELISA kit. Breath CO was measured using an
EC50-Micro Smokerlyzer (Bedfont Scientiﬁc, Medford, NJ).
Muscle lipid analysis. Skeletal muscle samples were dissected free of
extramuscular fat on ice as described by Guo et al. (23). Then, a sample of
muscle (70 mg) was lyophilized, weighed, added to 1 ml iced MeOH along
with internal standards of tripentadecanoic acid and dipentadencanoic acid,
and homogenized for 1 min on ice (Omni TH; Omni International, Marietta,
GA). Total lipids were then extracted as previously described (24). Samples
were shaken on a rotational mixer for 1.5 h at 4°C, then spun at 3,000 rcf for
15 to separate phases. The nonpolar bottom layer was dried down under N2
at 40°C, resuspended in chloroform, and added to aminopropyl solid-phase
extraction columns (Supelclean LC-NH2, 3 ml, Supelco Analytical). FFAs,
phospholipids, IMTGs, and DAGs were isolated using solid-phase extraction
based on the methods originally described by Kaluzny et al. (25). The FFA
fraction was methylated by adding 0.5 ml 2% sulfuric acid, capping, and
heating at 100°C for 1.5 h. Phospholipid, IMTG, and DAG fractions were
converted to fatty acid methyl esters by transmethylation using sodium
methoxide. Stable isotope ratios of
13C in fatty acid methyl esters were
measured at the Stable Isotope Laboratory at the University of California at
Davis using a GC-combustion isotope ratio mass spectrometer (GC/C-IRMS)
system composed of a Trace GC Ultra gas chromatograph (Thermo Electron,
Milan, Italy) with a SGE BPX70 column (30 m  0.25 mm internal diameter,
0.25 micron ﬁlm thickness) coupled to a Delta Plus Advantage isotope ratio
mass spectrometer through a GC/C-III interface (Thermo Electron, Bremen,
Germany). Enrichment was calculated based on a standard curve of known
enrichments and corrected for variations in abundance (26). Concentration
and composition analysis was performed on an HP 6890 GC with a 30-m DB-23
capillary column connected to an HP 5973 MS. Peak identities were deter-
mined by retention time and mass spectra compared with standards of known
composition.
Western blotting. Frozen skeletal muscle samples were weighed and ho-
mogenized on ice using a Kontes glass homogenizer (Kimble/Kontes, Vineland,
NJ) in a previously described buffer (27) containing protease (Roche Applied
Science, Indianapolis, IN) and phosphatase inhibitors (Sigma, St. Louis, MO).
Samples were agitated at 4°C for 2 h, then spun at 16,000 g for 15 to pellet
insoluble protein. Supernatant was saved and used to determine protein
concentration (Calbiochem, San Diego, CA).
Forty micrograms of sample protein and internal standard were run on an
SDS-PAGE 8% Bis-Tris gel (Invitrogen, Carlsbad, CA), transferred to a
polyvinylidene ﬂuoride membrane, and blocked with 5% BSA for1ha troom
temperature. Primary antibody incubations were performed in 5% BSA
overnight at 4°C, and a horseradish peroxidase–conjugated secondary anti-
body was incubated for1ha troom temperature. Enhanced chemilumines-
cence was used to visualize protein bands of interest. Intensity of protein
bands was captured using an AlphaImager 3300 and quantiﬁed using Fluor-
Chem software (Alpha Innotech, San Leandro, CA). Protein bands were
normalized to 
-actin as a loading control and then normalized to an internal
standard that was run on each gel. Rabbit anti–4-hydroxynonenal antibody
was a generous gift from Dr. Dennis Peterson. Other antibodies were
purchased from cell signaling (Danvers, MA) and Santa Cruz Biotechnology
(Santa Cruz, CA). Secondary antibodies were from Bio-Rad (Bio-Rad, Her-
cules, CA).
RT-PCR. Total RNA was extracted from homogenized muscle biopsies using
the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was analyzed and quantiﬁed
using the Experion System (Bio-Rad). Reverse transcription was performed
using 45 ng total RNA with iScript cDNA Synthesis Kit (Bio-Rad). Quantitative
PCR was performed using primer sets for genes of interest or two reference
genes (all spanned exon-exon boundaries) and ABsolute Blue QPCR SYBR
Green Fluorescein Mix (Thermo Fisher Scientiﬁc, Waltham, MA) following
manufacturer’s protocol. Reactions were run in duplicate on an iQ5 Real-Time
PCR Detection System (Bio-Rad) along with a no-template control per gene.
We performed RT-PCR to determine differences in gene expression that may
explain the insulin resistant phenotype of smokers. We determined differences
TABLE 1
Anthropometric and metabolic characteristics of the study
population
Nonsmokers Smokers P
N (men/women) 18 (11/7) 14 (12/2)
Age (years) 20.1  0.4 21.2  0.7 0.17
BMI (kg/m
2) 22.6  0.4 22.9  0.4 0.40
Body fat (%) 20.2  2.1 19.7  2.2 0.86
Fasting glucose (mg/dl) 82.0  1.8 85.2  0.9 0.16
FFAs (mol/l) 738  66 716  45 0.79
Lactate (mmol/l) 0.75  0.1 0.84  0.1 0.35
Insulin (U/ml) 4.4  0.4 5.5  0.4 0.06
Glucagon (pg/ml) 63  45 3  4 0.10
Triglycerides (mg/dl) 67  9 117  13§ 0.001
Norepinephrine (pg/ml) 220  12 280  59 0.39
Epinephrine (pg/ml) 27  23 3  5.1 0.46
Adiponectin (pg/ml) 12.5  1.4 11.9  0.9 0.97
TNF-
 (pg/ml) 1.4  0.1 1.6  0.2 0.38
IL-6 (pg/ml) 1.67  0.3 4.61  1.1 0.007
Cigarettes per day (n) 0 18.0  0.8§ 0.001
Breath CO (ppm) 3.1  0.5 27.2  2.4§ 0.001
Urinary cotinine (ng/ml) 3.8  1.2 342.6  51§ 0.001
Glucose Ra
(mg  kg
1  min
1) 1.75  0.08 1.75  0.08 0.98
Values are means  SE. §  signiﬁcantly different between nonsmok-
ers and smokers, P  0.05. Ra, rate of appearance.
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CoA desaturase 1 [SCD1]), IMTG synthesis (diacylglycerol acyltransferase 1
[DGAT1]), IMTG degradation (adipose triglyceride lipase [ATGL]), a transcrip-
tion factor regulating genes controlling lipogenesis (sterol regulatory element
binding protein 1c [SREBP1c]), a nuclear transcription factor inﬂuencing fatty
acid oxidation (peroxisome proliferator–activated receptor 
 [PPAR-
]) and
synthesis (PPAR-), a nuclear binding partner to PPAR (retinoid X receptor 
[RXR-]), a transcription factor regulating the PPAR/RXR dimer (forkhead
box class 01 [FOXO1]), and markers of macrophage inﬁltration (monocyte
chemoattractant protein 1 [MCP-1]) and local inﬂammation (IL-6). RNA
expression data were normalized to levels of ribosomal protein L13a
(RPL13A) and ubiquitin C (UBC) using the comparative threshold cycle
method. The following forward primers were used in this analysis:
SCD1 (AACTGGTGATGTTCCAGAGGAGGT)
FOXO1 (TCCCACACAGTGTCAAGACAACGA)
DGAT1 (ATGTCTTTGCTGTGGCTGCATTCC)
ATGL (ATCCCACTTCAACTCCAAGGACGA)
SREBP-1c (GGAGCCATGGATTGCACTTT)
PPAR-
 (TGCACTGGAACTGGATGACAGTGA)
PPAR- (TCATCCTCTCAGGAAAGGCCAGTA)
RXR- (AGTCTCCCAGTGGAGCATTGAACA)
IL-6 (AAATTCGGTACATCCTCGACGGCA)
RPL13A (CCTGGAGGAGAAGAGGAAAGAGA)
UBC (ATTTGGGTCGCGGTTCTTG)
Plasma palmitate and glucose isotope analysis. Plasma glucose derivati-
zation and analysis was determined as previously described (27). Methylation
and extraction of plasma palmitate was performed as previously described
(28). Samples were run on an HP 6890 GC with a 30-m DB-23 capillary column
connected to an HP 5973 MS. Enrichments were calculated based on a
standard curve of known enrichments and corrected for variations in abun-
dance (26).
Isotope ratio mass spectrometry. Two milliliters of breath CO2 was
transferred into a 20-ml exetainer for measurement of
13CO2/
12CO2 with
continuous ﬂow isotope ratio mass spectrometry (IRMS) (Delta V, Thermo
Electron). Each sample was injected (1.2 l per injection) in duplicate for
isotope ratio analyses, with an average standard deviation for all injections of
0.0001 atom percent.
Calculations. IMTG fractional synthesis rate was calculated as previously
described (29). The average enrichment of the skeletal muscle FFA pool
during the 4-h infusion was used to represent the precursor pool from which
IMTG was synthesized.
IMTG FSR (%/hr) 
EIMTG palm(t1)  EIMTG palm(t0)
EFFApalm(t1)

1
4
 100
DAG fractional synthesis rates were calculated in a similar way.
DAG FSR (%/hr) 
EDAG palm(t1)  EDAG palm(t0)
EFFApalm(t1)

1
4
 100
Where EIMTG palm(t1) is the enrichment of palmitate in the IMTG pool after 4 h
of infusion, EIMTG palm(t0) is the enrichment of background palmitate in the
IMTG pool, EDAG palm(t1) is the enrichment of palmitate in the muscle DAG
pool after4ho finfusion, and EDAG palm(t0) is the enrichment of background
palmitate in the muscle DAG pool. EFFApalm(t1) is the enrichment of skeletal
muscle palmitate in the FFA pool. The enrichment of stearate in IMTG and
DAG during the 4-h muscle biopsy was used to represent the background
enrichment of palmitate before isotope infusion without having to take a
background biopsy as previously described (29). Skeletal muscle FFA was
assumed to be the precursor pool for IMTG and DAG synthesis (29).
% Saturation of IMTG and DAG  laurate  myristate  palmitate
 stearate/FFA species  100
Where FFA represents concentration of individual FFA species in IMTG and
DAG after transmethylation.
Palmitate and glucose rate of disappearance and palmitate rate of oxida-
tion were calculated using steady-state kinetics and a whole-body estimate of
carbon label retention as previously described (30). Palmitate incorporation
rate into IMTG was calculated as the product of IMTG fractional synthesis rate
(FSR) and palmitate pool size in IMTG. Fat-free mass was used to extrapolate
skeletal muscle palmitate IMTG storage to the whole body.
Statistics. Data are presented as means  SE. Differences in normally
distributed data between smokers and nonsmokers were analyzed using a
one-way ANOVA (SPSS, Chicago, IL). Non-normally distributed data were log
transformed before analysis using a one-way ANOVA. P values were corrected
for multiple comparisons using the Bonferroni method. Differences between
IMTG and DAG fractional synthesis rates within individuals were determined
using a paired t test. An 
 level of 0.05 was used throughout.
RESULTS
Subject characteristics and demographic information
are shown in Table 1. All subjects were college-aged
men and women with similar BMI, percent body fat, and
blood metabolites. Smokers reported smoking almost
one pack of cigarettes per day. There was an approxi-
mate doubling of fasting blood triglyceride concentra-
tion in smokers compared with nonsmokers, as well as
signiﬁcantly greater IL-6, urinary cotinine, and breath
CO concentrations.
Insulin sensitivity was signiﬁcantly lower in smokers
compared with nonsmokers (Fig. 1, P  0.03). Contrary to
our hypothesis, we did not ﬁnd a difference in resting
concentration or FSR of IMTG in smokers compared with
nonsmokers (Fig. 2A and B). However, composition of
IMTG differed between groups, with signiﬁcantly greater
proportion of saturated fatty acid species in smokers
compared with nonsmokers (Fig. 2C, P  0.02). There was
also a signiﬁcant inverse relationship between IMTG con-
tent and FSR (Fig. 2D).
Skeletal muscle DAG concentration was also not
different between groups, suggesting alterations in DAG-
stimulated protein kinase C activation cannot explain the
insulin resistance in smokers (Fig. 3A). The FSR of DAG
was also not different between groups (Fig. 3B). The FSR
of DAG was signiﬁcantly greater than IMTG in both groups
(P  0.001). Similar to IMTG, saturation of DAG was
signiﬁcantly greater in smokers compared with nonsmok-
ers (Fig. 3C, P  0.03).
We found signiﬁcantly lower expression of PPAR- and
signiﬁcantly higher expression of MCP-1 in smokers com-
pared with nonsmokers (Fig. 4, P  0.05). There were trends
(P  0.10) toward higher expression of FOXO1 and lower
DGAT1 and RXR- in smokers compared with nonsmokers.
Table 2 shows a summary of Western blot data, which was
not signiﬁcantly different between groups, including total
IRS-1 content. The only signiﬁcant difference was signiﬁ-
cantly greater content of insulin receptor substrate (IRS)-1
Ser
636 phosphorylation, which is inhibitory to insulin signal-
ing in smokers compared with nonsmokers (Fig. 5, P 
0.002). This difference was signiﬁcant even after correcting
for multiple comparisons using Bonferroni.
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FIG. 1. Insulin sensitivity measured using the Bergman minimal model
in nonsmokers () and smokers (f). Values are means  SE. § 
signiﬁcantly different than nonsmokers, P < 0.05.
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between groups (control subjects  1.4  0.1 mol  kg
1 
min
1; smokers  1.3  0.1 mol  kg
1  min
1). Palmitate
turnover was signiﬁcantly higher in smokers compared with
nonsmokers (Fig. 6A, P  0.001). Breath
13CO2 enrichment
was signiﬁcantly greater in smokers compared with
nonsmokers (smokers  1.117  0.001 Atom%, control
subjects  1.112  0.001 Atom%; P  0.001). The rate of
oxidation of plasma palmitate was also signiﬁcantly
higher in smokers compared with nonsmokers (Fig. 6B,
P  0.01). However, the rate of palmitate incorporation
into IMTG was not signiﬁcantly different between groups
(Fig. 6C).
DISCUSSION
Many studies have demonstrated a detrimental effect of
smoking on insulin action. Data from epidemiologic
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FIG. 2. Intramuscular triglyceride concentration (A), fractional syn-
thesis rate (B), saturation (C) in nonsmokers () and smokers (f).
Values are means  SE. §  signiﬁcantly different than nonsmokers,
P < 0.05. The signiﬁcant relationship between IMTG concentration
and turnover in all subjects is shown in panel (D).
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insulin sensitivity in middle-aged smokers (4–6). We are
the ﬁrst to report chronic cigarette smoking promotes
insulin resistance in young, otherwise healthy college-
aged men and women. Major ﬁndings from this study
suggest saturation of intramuscular lipids, independent
of concentration or turnover, may be related to insulin
action. Further, smoking resulted in basal inhibition of
insulin signaling. The induction of such metabolic de-
fects at a young age will surely result in profound and
premature untoward health effects.
In addition to lower insulin action, smokers have
greater delivery of plasma FFA (16,17) and lipoproteins
(16,18) to skeletal muscle. Therefore, we hypothesized
smoking may promote IMTG and DAG accumulation.
However, we found no differences in IMTG or DAG
concentration between groups. These data add to other
studies ﬁnding a dissociation between IMTG concentra-
tion and insulin action (31,32) and support the notion
that IMTG may only be a marker of insulin resistance
rather than a cause. Similar DAG concentrations were
surprising considering data linking DAG accumulation
with insulin resistance (33). Supporting a lack of DAG-
induced insulin resistance were similar PCK and 
content between groups. However, these data are from
whole-cell lysates, and it is possible that differences in
cytosolic versus sarcolemmal localization went unno-
ticed. Together, our data suggest increased skeletal
muscle IMTG and DAG concentrations are not related to
insulin resistance in college-aged chronic smokers.
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FIG. 4. RT-PCR summary of skeletal muscle biopsy data comparing
nonsmokers () with smokers (f). Values are means  SE. § 
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FIG. 3. Intramuscular DAG concentration (A), fractional synthesis rate (B), and saturation (C) in nonsmokers () and smokers (f). D: Skeletal
muscle DAG composition in nonsmokers and smokers. Values are means  SE. §  signiﬁcantly different than nonsmokers, P < 0.05.
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tively related to insulin sensitivity (14,15). Increased syn-
thesis rates of IMTG may enhance FFA clearance and
decrease ceramide and long-chain acyl-CoA synthesis,
which may increase insulin action (34,35). In support of
this, recent evidence indicates increasing IMTG synthesis
in rodents and humans protects against fat-induced insulin
resistance (31,32). In the current study, however, we found
no differences in IMTG and DAG FSR between smokers
and nonsmokers, suggesting rates of IMTG and DAG
synthesis may not be related to insulin sensitivity in this
population. Further, we found no change in whole-body
glucose kinetics between groups similar to some (17) but
not all previous studies (36). Smokers had increased
plasma palmitate turnover as has been shown before in
older smokers (17). Our data on breath V
13CO2 and
13C
palmitate incorporation into IMTG suggests that the in-
creased plasma palmitate disposal in smokers is oxidized
and not stored as IMTG. These data suggest decreased
mitochondrial FFA oxidation and mitochondrial dysfunc-
tion does not play a major role in smoking-induced insulin
resistance.
Interestingly, IMTG and DAG were signiﬁcantly more
saturated in smokers compared with nonsmokers. Ini-
tially, we thought this could be explained by increased
habitual consumption of saturated fat in smokers. How-
ever, there were no differences in overall phospholipid
composition, which has been used as a surrogate measure
of dietary lipid intake, between groups (37). Less muscle
lipid desaturation in smokers is unlikely, as the expression
and protein content of SCD1, which converts saturated
palmitoyl-CoA and stearoyl-CoA to monounsaturated
palmitoleoyl-CoA and oleoyl-CoA, respectively, was not
different between groups. Although indirect, a common
surrogate for SCD1 activity are ratios of 16:1 to 16:0 and
18:1 to 18:0 (38). None of these ratios were signiﬁcantly
different for IMTG and DAG pools between smokers and
nonsmokers. Therefore, it is unlikely that changes in SCD1
content or activity explain alterations in muscle lipid
saturation, but the exact mechanism by which smoking
changes neutral lipid storage is not known. The impor-
tance of saturated lipids on tissue insulin action was
highlighted by a study that developed a transgenic Elovl6
(elongation of long-chain fatty acids family member 6)
knockout mouse (39). They found no change in hepatic
triglyceride content but a signiﬁcant change in triglyceride
composition and increased hepatic insulin action. We extend
these data to humans and suggest IMTG and DAG composi-
tion may inﬂuence insulin sensitivity in skeletal muscle.
We analyzed many potential mediators of intracellular
insulin resistance to explain why smokers were insulin
resistant. There was no indication of plasma inﬂammation,
lipid toxicity, lipid peroxidation, or endoplasmic reticulum
stress. The only measure signiﬁcantly different between
groups was greater IRS-1 Ser
636 phosphorylation in smok-
ers compared with nonsmokers. This difference may ex-
plain decreased insulin action in smokers because of basal
inhibition of insulin signaling.
There are several known mechanisms that lead to
phosphorylation of Ser
636 on IRS-1. Increased mammalian
target of rapamycin (mTOR) and/or p44/42 mitogen-
activated protein kinase (MAPK, a.k.a. ERK1/2) activity
promotes insulin resistance by phosphorylating this spe-
ciﬁc site on IRS-1. We measured the phosphorylation state
of the downstream kinase for mTOR/p70s6k and found
no differences between groups. Further, we measured
ERK1/2 phosphorylation and found no differences be-
tween groups. Therefore, these data imply chronic signal-
ing through mTOR or ERK1/2 cannot explain increased
IRS-1 Ser
636 phosphorylation in smokers compared with
nonsmokers. However, our data are consistent with tran-
sitory nicotine-stimulated ERK1/2 activity that could result
in basal IRS-1 Ser
636 phosphorylation.
TABLE 2
Summary of Western blot data from resting skeletal muscle
biopsies from nonsmokers and smokers
Nonsmokers Smokers P
GRP78 0.93  0.12 0.85  0.10 0.65
ADRP 0.74  0.08 0.76  0.07 0.84
MAP4K4 1.43  0.20 1.84  0.30 0.18
4-HNE 0.85  0.13 0.78  0.12 0.87
SDH 1.23  0.08 1.16  0.08 0.52
PGC1
 0.60  0.05 0.67  0.06 0.36
TLR2 0.98  0.11 1.3  0.16 0.12
SOCS1 0.76  0.05 0.74  0.04 0.48
PKC 0.74  0.13 1.02  0.33 0.78
PKC 0.42  0.04 0.52  0.05 0.15
Phospho-p44 MAPK/total 0.51  0.07 0.38  0.08 0.15
Phospho-ser307/IRS1 total 0.67  0.16 0.81  0.17 0.54
Phospho-AMPK/total 1.04  0.23 0.86  0.18 0.56
Phospho IKKalpha/total 0.84  0.15 0.77  0.22 0.85
Phospho-JNK/total 0.63  0.05 0.68  0.06 0.50
Phospho-p70S6k/total 1.10  0.34 0.80  0.10 0.96
Values are means of arbitrary units  SE. GRP78, glucose-regulated
protein 78; ADRP, adipose differentiation–related protein; MAP4K4,
mitogen-activated protein kinase kinase kinase kinase 4; 4-HNE,
4-hydroxynonenal; SDH, succinate dehydrogenase; PGC1a, prolifera-
tor-activated receptor  coactivator-1a; TLR2, toll-like receptor 2;
SOCS1, suppressor of cytokine signaling 1; AMPK, AMP-activated
protein kinase; IKK, IB kinase; JNK, c-Jun N-terminal kinase.
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FIG. 5. Ser
636 phosphorylation of IRS-1 in nonsmokers () and smok-
ers (f). There was not a signiﬁcant difference in total IRS-1 content
between groups. Values are means  SE. Nonsmokers  0.73  0.08,
smokers  1.14  0.9, AU. §  signiﬁcantly different than nonsmokers,
P < 0.05.
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because of nicotine, which promotes insulin resistance
following direct infusion in humans (40). However, the
mechanism behind smoking or nicotine-induced insulin
resistance is not known. Recent evidence indicates nico-
tine increases ERK1/2 phosphorylation in a wide variety of
cells (41–43). Further, the increase in ERK1/2 phosphory-
lation is transient, starting after 2 min of nicotine expo-
sure, peaking after 10 min, and decreasing to basal
values after 15–30 min of continued exposure (41–43).
Ser
636 phosphorylation of IRS-1 induced by ERK1/2 activ-
ity has been reported in primary human muscle cell
cultures from individuals with type 2 diabetes (44) and
following TNF
-induced insulin resistance in 3T3L-1 adi-
pocytes (45). Interestingly, ERK1/2 phosphorylation can
decrease to basal levels before measuring increased serine
phosphorylation of IRS-1 in 3T3L1 adipocytes (45). The
current data are consistent with nicotine exposure during
tobacco smoking promoting insulin resistance via Ser
636
phosphorylation of IRS-1, induced via transient ERK1/2
stimulation.
Skeletal muscle RT-PCR analysis supports other mech-
anisms may also be working to promote insulin resistance
in smokers. Expression of MCP-1 was increased in skeletal
muscle from smokers compared with nonsmokers. MCP-1
is a chemokine produced by adipocytes, vascular cells,
and skeletal muscle, which promotes macrophage entry
into tissues and itself may promote insulin resistance (46).
These data suggest smoking may promote macrophage
inﬁltration in skeletal muscle, possibly promoted by smok-
ing-induced endothelial damage (47), which may result in
local cytokine production and insulin resistance (48).
PPAR- expression was also decreased in smokers com-
pared with nonsmokers. We found a trend for decreased
RXR- expression, which dimerizes with PPAR- in the
nucleus, and a nonsigniﬁcant increase in FOXO1 expres-
sion in smokers, which negatively regulates PPAR-/RXR
promoter activity (49). Muscle-speciﬁc knockout of
PPAR- results in an insulin-resistant phenotype (50).
Therefore, these changes point to alterations in down-
stream targets of PPAR- as potential mechanisms in
smoking-induced insulin resistance. Abbasi et al. (51)
treated insulin-resistant smokers for 12 weeks with piogli-
tazone and found increased insulin sensitivity and de-
creased plasma triglyceride concentrations. These data
imply increased PPAR- stimulation may reverse part of
the insulin resistance in smokers and suggest decreased
muscle PPAR- may be important in insulin resistance in
smokers.
There are several limitations to this study. The sample
size studied was small, which may have limited our ability
to measure small differences between groups. We chose
subjects who were sedentary and engaged in planned
physical activity less than 3 h/week. Even though succi-
nate dehydrogenase content was similar between groups,
it is possible that differences in physical activity may have
inﬂuenced our results.
In conclusion, chronic cigarette smokers were less
insulin sensitive compared with control subjects that did
not smoke. There were no differences in IMTG or DAG
content or synthesis rates, but smokers had increased
saturation of skeletal muscle lipids. Insulin resistance in
smokers may be because of increased basal inhibition of
insulin signaling via Ser
636 phosphorylation of IRS-1.
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